Prevention and management of lung cancer in China

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population

(2012) JING ZHANG et al.   RESPIROLOGY

COPD in China

(2011) Xiaocong Fang et al.   CHEST

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Prior lung disease and lung cancer risk in an occupational-based cohort in Yunnan, China

(2011) Ya-Guang Fan et al.   LUNG CANCER

A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese

(2011) Zhibin Hu et al.   NATURE GENETICS

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

(2010) Jie Zhang et al.   CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

(2010) Yihua Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Environmental health in China: progress towards clean air and safe water

(2010) Junfeng Zhang et al.   LANCET

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhalation exposure to ambient polycyclic aromatic hydrocarbons and lung cancer risk of Chinese population

(2009) Yanxu Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA